

FORM PTO-1449 (Modified)

Sheet 1 of 7

ATTY. DOCKET NO.

18810-82302

SERIAL NO.

UNASSIGNED

09/898,779

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

APPLICANT: KENT D. TAYLOR ET AL.

FILING DATE: HEREWITH

GROUP ART UNIT NO.

1655

DC978 U.S. PRO  
09/898779

07/03/01

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
gy	4,683,195	07/28/87	Mullis et al.			
	4,683,202	07/28/87	Mullis			
	4,988,617	91/29/91	Landegren			
	5,384,242	01/24/95	Oakes			

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	Translation	
					YES	NO

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

gy	1.	Anguita, M. et al., <i>Comparison of the effectiveness of lovastatin therapy for hypercholesterolemia after heart transplantation between patients with and without pretransplant atherosclerotic coronary artery diseases</i> , <u>Am. J. Cardiol.</u> , 74(8):776-779 (Oct. 15, 1994).
	2.	Alván, Gunnar, <i>Editorial, Genetic polymorphisms in drug metabolism</i> , <u>Journal of Internal Medicine</u> , Vol. 231, pp. 571-573, (1992).
	3.	Ballantyne, C. M., <i>Low-density lipoproteins and risk for coronary artery disease</i> , <u>Am. J. Cardiol.</u> , 82(9A):3Q-12Q (Nov 5, 1998).
	4.	Bell, D. S., <i>A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia</i> , <u>Clin Ther.</u> 17(5):901-910 (Sep 1995) ABSTRACT ONLY.

EXAMINER

J. Goldberg

DATE CONSIDERED

1/9/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.

18810-82302

SERIAL NO.

UNASSIGNED

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

APPLICANT: KENT D. TAYLOR ET AL.

FILING DATE: HEREWITH

GROUP ART UNIT NO. - -

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

5.	Bellosta, S. et al., <i>HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages</i> , <i>Arterioscler Thromb Vasc Biol</i> , 18(11):1671-8 (Nov 1998).
6.	Butowski, P.F. et al., <i>Usual care dietary practice, achievement and implications for medication in the management of hypercholesterolaemia. Data from the U.K. Lipid Clinics Programme.</i> , <i>Eur Heart J.</i> , 19(9):1328-33 (Sep 1998).
7.	Campeau, Lucien et al., <i>The Relation of Risk Factors to the Development of Atherosclerosis in Saphenous-vein Bypass Grafts and the Progression of Disease in the Native Circulation</i> , <i>The New England Journal of Medicine</i> , Vol. 311, No. 21, pp. 1329-32 (Nov 22, 1984).
8.	Campeau, Lucien et al., <i>The Effect of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation on Obstructive Changes in Saphenous-vein Coronary-Artery Bypass Grafts</i> , <i>The New England Journal of Medicine</i> , Vol. 336, No. 3, pp. 153-162 (Jan 16, 1997).
9.	Cannon, C. P., <i>Advances in the medical management of acute coronary syndromes</i> , <i>Curr Opin Cardiol</i> , 13(5):327-47 (Sep 1998). ABSTRACT ONLY.
10.	Chen, L. et al., <i>HindIII DNA polymorphism in the lipoprotein lipase gene and plasma lipid phenotypes and carotid artery atherosclerosis</i> , <i>Hum Genet</i> , 98(5):551-556 (Nov 1996).
11.	Chuat, J. C. et al., <i>The lipoprotein lipase-encoding human gene: sequence from intron-6 to intron-9 and presence in intron-7 of a 40-million-year-old Alu sequence</i> , <i>Gene</i> , 110(2):257-61 (Jan 15, 1992). ABSTRACT ONLY.
12.	Clark, A. G. et al., <i>Haplotype structure and population genetic inferences from nucleotide-sequence variation in human lipoprotein lipase</i> , <i>Am J. Hum Genet</i> , 63(2):595-612 (Aug 1998).
13.	Deeb, Samir S., et al., <i>Structure of the Human Lipoprotein Lipase Gene</i> , <i>Biochemistry</i> , Vol. 28, No. 10, pp. 4131-35 (May 16, 1989).
14.	Durrington, P. N., <i>Can we afford to treat hyperlipidaemia as we should? Strategies for rational treatment</i> , <i>Atherosclerosis</i> , 139 Suppl 1:S1-5 (Sep 1998). ABSTRACT ONLY.
15.	Farmer, J. A. et al., <i>Currently available hypolipidaemic drugs and future therapeutic developments</i> , <i>Baillieres Clin Endocrinol Metab</i> , 9(4):825-847 (Oct 1995).

EXAMINER

DATE CONSIDERED

J. Goldberg

1/9/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

7316.1

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
18810-82302SERIAL NO. :  
UNASSIGNEDLIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

APPLICANT: KENT D. TAYLOR ET AL.

FILING DATE: HEREWITH

GROUP ART UNIT NO. - -

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

16.	Farmer, J. A. et al., <i>Choosing the right lipid-regulating agent. A guide to selection, Drugs</i> , 52(5):649:661 (Nov 1996).
17.	Farmer, J. A., <i>Economic implications of lipid-lowering trials: current considerations in selecting a statin</i> , <i>Am J. Cardiol</i> , 82(6A):26M-31M (Sep 24 1998).
18.	Farmer, J. A., <i>Aggressive lipid therapy in the statin era</i> , <i>Prog Cardiovasc Dis</i> , 41(2):71-94 (Sep-Oct 1998).
19.	Farnier, M. et al., <i>Current and future treatment of hyperlipidemia: the role of statins</i> , <i>Am J. Cardiol</i> , 82(4B):3J-10J (Aug 27, 1998).
20.	Fisher, R. M. et al., <i>Common variation in the lipoprotein lipase gene: effects on plasma lipids and risk of atherosclerosis</i> , <i>Atherosclerosis</i> , 135(2):145-59 (Dec 1997). ABSTRACT ONLY.
21.	Funke Harald et al., <i>The low down on lipoprotein lipase</i> , <i>Nature Genetics</i> , Vol. 10, pp. 6-7 (May 1995).
22.	Garg, A. et al., <i>Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus</i> , <i>N Engl J. Med</i> , 318(2):81-86 (Jan 1988).
23.	Gerdes, C. et al., <i>Polymorphisms in the lipoprotein lipase gene and their associations with plasma lipid concentrations in 40-year-old Danish men</i> , <i>Circulation</i> , 92(7):1765-1769 (Oct 1995).
24.	Goldberg, R. et al., <i>Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus</i> , <i>Am J Cardiol</i> , 66(8):16B-21B (Sep 18, 1990).
25.	Guyton, J. R., et al., <i>Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia</i> , <i>Am J Cardiol</i> , 82(6):737-43 (Sep 15, 1998).
26.	Gylling, H. et al., <i>Treatment of lipid disorders in non-insulin-dependent diabetes mellitus</i> , <i>Curr Opin Lipidol</i> , 8(6):342-7 (Dec 1997).
27.	Hansson, L. et al., <i>Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group</i> , <i>Lancet</i> , 351(9118):1755-62 (Jun 13, 1998).
28.	Hayden, M. R. et al., <i>Molecular genetics of human lipoprotein lipase deficiency</i> , <i>Mol Cell Biochem</i> , 113(2):171-176 (Aug 18, 1992).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

7316.1

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
18810-82302SERIAL NO.  
UNASSIGNEDLIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

APPLICANT: KENT D. TAYLOR ET AL.

FILING DATE: HEREWITH

GROUP ART UNIT NO. - -

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

29.	Heizmann, Camilla et al., <i>DNA polymorphism haplotypes of the human lipoprotein lipase gene: possible association with high density lipoprotein levels</i> , <u>Human Genetics</u> , Vol. 86, pp. 578-84 (1991).
30.	Humphries, S. E. et al., <i>Lipoprotein lipase gene variation is associated with a paternal history of premature coronary artery disease and fasting and postprandial plasma triglycerides: the European Atherosclerosis Research Study (EARS)</i> , <u>Arterioscler Throm Vasc Biol</u> , 18(4):526-34 (Apr 1998).
31.	Huse, D. M. et al., <i>Cost-effectiveness of statins</i> , <u>Am J. Cardiol</u> , 82(11):1357-63 (Dec 1, 1998).
32.	Jukema, J. Wouter et al., <i>The Asp<sub>9</sub> Asn Mutation in the Lipoprotein Lipase Gene is Associated with Increased Progression of Coronary Atherosclerosis</i> , <u>Circulation</u> , Vol. 94, No. 8, pp. 1913-18 (Oct 15, 1996).
33.	Kirchgessner, Todd G. et al., <i>The sequence of cDNA Encoding Lipoprotein Lipase</i> , <u>The Journal of Biological Chemistry</u> , Vol. 262, No. 18, pp. 8463-8466 (Jun 25, 1987).
34.	Kirchgessner, T. G. et al., <i>Organization of the human lipoprotein lipase gene and evolution of the lipase gene family</i> , <u>Proc Natl Acad Sci USA</u> , Vol. 86, No. 24, pp. 9647-9651 (Dec 1989).
35.	Kleyn, Patrick W. et al., <i>Genetic Variation as a Guide to Drug Development</i> , <u>Science</u> , Vol. 281, pp. 1820-21 (Sep 18, 1998).
36.	Kornitzer, M., <i>Primary and secondary prevention of coronary artery disease: a follow-up on clinical controlled trials</i> , <u>Curr Opin Lipidol</u> , 9(6):557-64 (Dec 1998). ABSTRACT ONLY.
37.	Kozaki, K. et al., <i>Mutational analysis of human lipoprotein lipase by carboxy-terminal truncation</i> , <u>J Lipid Res</u> , 34(10):1765-1772 (Oct 1993). ABSTRACT ONLY.
38.	Kuivenhoven, Jan Albert et al., <i>The role of a Common Variant of the Cholesteryl Ester Transfer Protein Gene in the Progression of Coronary Atherosclerosis</i> , <u>The New England Journal of Medicine</u> , Vol. 338, No. 2, pp. 86-93 (Jan 8, 1998).
39.	LaRosa, J. C., <i>The role of diet and exercise in the statin era</i> , <u>Prog Cardiovasc Dis</u> , 41(2):137-50 (Sep-Oct 1998).
40.	McKenney, J. M., <i>Lovastatin: a new cholesterol-lowering agent</i> , <u>Clin Pharm</u> , 7(1):21-36 (Jan 1988).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

7316.1

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
18810-802302SERIAL NO.  
UNASSIGNEDLIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

APPLICANT: KENT D. TAYLOR ET AL.

FILING DATE: HERewith

GROUP ART UNIT NO. - -

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

41.	Mori, A. et al., <i>Development of a direct DNA sequencing method for detecting heterozygous mutations of the human lipoprotein lipase gene</i> , <u>Clin Biochem</u> , 30(4):315-324, (Jun 1997). ABSTRACT ONLY.
42.	Neitzel, Gary F. et al., <i>Atherosclerosis in Aortocoronary Bypass Grafts, Morphologic Study and Risk Factor Analysis 6 to 12 Years After Surgery</i> , <u>Arteriosclerosis</u> , Vol. 6, No. 6, pp. 594-600 (Nov/Dec 1986).
43.	Nickerson, Deborah A. et al., <i>DNA sequence diversity in a 9.7-kb region of the human lipoprotein lipase gene</i> , <u>Nature Genetics</u> , Vol. 19, No. 3, pp. 233-240 (Jul 1998).
44.	Oka, Kazuhiro et al., <i>Structure and polymorphic map of human lipoprotein lipase gene</i> , <u>Biochimica et Biophysica Acta</u> , Vol. 1049, pp. 21-26 (1990).
45.	Olsson, A. G., <i>Addressing the challenge</i> , <u>Eur Heart J</u> , 19 Suppl M: M29-35 (Oct 1998).
46.	Peacock, Rachel E. et al., <i>Associations between lipoprotein lipase gene polymorphisms and plasma correlations of lipids, lipoproteins and lipase activities in young myocardial infarction survivors and age-matched healthy individuals from Sweden</i> , <u>Atherosclerosis</u> , Vol. 97, pp. 171-185 (1992).
47.	Pedersen, T. R. et al., <i>Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal</i> , <u>Drug Saf</u> , 14(1):11-24 (Jan 1996). ABSTRACT ONLY.
48.	Pitsavos, C. E. et al., <i>Effects of pravastatin on thoracic aortic atherosclerosis in patients with heterozygous familial hypercholesterolemia</i> , <u>Am J Cardiol</u> , 82(12):1484-8 (Dec 15, 1998).
49.	Reymer, P. W. et al., <i>A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis</i> , <u>Nat Genet</u> , 10(1):28-34 (May 1995).
50.	Rifkind, B. M., <i>Clinical trials of reducing low-density lipoprotein concentrations</i> , <u>Endocrinol Metab Clin North Am</u> , 27(3):585-95, viii-ix (Sep 1998). ABSTRACT ONLY.
51.	Rudski, L. et al., <i>Systemic immune reactions to HMG-CoA reductase inhibitors. Report of 4 cases and review of the literature</i> , <u>Medicine (Baltimore)</u> , 77(6):378-83 (Nov 1998). ABSTRACT ONLY.

EXAMINER

J. Goldberg

DATE CONSIDERED

1/9/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

7316.1

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
18810-82302SERIAL NO.  
UNASSIGNEDLIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

APPLICANT: KENT D. TAYLOR ET AL.

FILING DATE: HEREWITH

GROUP ART UNIT NO. - -

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

52.	Santamarina-Fojo, Silvia et al., <i>Structure, function and role of lipoprotein lipase in lipoprotein metabolism</i> , <u>Genetics and Molecular Biology</u> , <u>Current Opinion in Lipidology</u> , Vol.5, pp. 117-125 (1994).
53.	Sass, C. et al., <i>Evidence for a cholesterol-lowering gene in a French-Canadian kindred with familial hypercholesterolemia</i> , <u>Hum Genet</u> , 96(1):21-26 (Jul 1995).
54.	Scheen, A. J., <i>[Drug clinics. Drug of the month. Atorvastatin]</i> , <u>Rev Med Liege</u> , 53(6):374-7 (June 1998). ABSTRACT ONLY.
55.	Szucs, T. D., <i>Pharmaco-economic aspects of lipid-lowering therapy: is it worth the price?</i> , <u>Eur Heart J</u> , 19 Suppl M:M22-8 (Oct 1998).
56.	Tikkanen, M. J. et al., <i>Treatment of familial and non-familial hypercholesterolaemia: a review of HMG-CoA reductase inhibitors and probucol</i> , <u>Eur Heart J</u> , 8 Suppl E: 97-101 (Aug 1987). ABSTRACT ONLY.
57.	The Medical Research Council's General Practice Research Framework, <i>Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General practice Research Framework</i> , <u>Lancet</u> , 351(9098):233-41 (Jan 24 1998).
58.	Vesell, Elliot S., <i>Therapeutic Lessons from Pharmacogenetics</i> , <u>Annals of Internal Medicine</u> , Vol. 126, No. 8, pp. 653-5 (Apr 15, 1997).
59.	von Keutz, E. et al., <i>Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor</i> , <u>Am J. Cardiol</u> , 82(4B):11J-17J (Aug 27, 1998).
60.	Weinshilboum, Richard, <i>Methyltransferase Pharmacogenetics</i> , <u>Pharmac Ther</u> , Vol. 43, pp. 77-90 (1989).
61.	Wheeler, D. C., <i>Are there potential non-lipid-lowering uses of statins?</i> , <u>Drugs</u> , 56(4):517-22 (Oct 1998).
62.	Wion, Karen L. et al., <i>Human Lipoprotein Lipase complementary DNA Sequence</i> , <u>Science</u> , Vol. 235, pp. 1638-41 (Mar 27, 1987).
63.	Zuliani, Giovanni et al., <i>Tetranucleotide repeat polymorphism in the LPL gene</i> , Department of Molecular Genetics, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235 USA (1990).

EXAMINER

J. Goldberg

DATE CONSIDERED

1/9/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

7316.1

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
18810-82302SERIAL NO.  
UNASSIGNEDLIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

APPLICANT: KENT D. TAYLOR ET AL.

FILING DATE: HEREWITH

GROUP ART UNIT NO. - -

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	64.	<del>Ahn, Y. I. et al., Two DNA polymorphisms in the lipoprotein lipase gene and their associations with factors related to cardiovascular disease, J Lipid Res, 34(3):421-8 (Mar 1993). ABSTRACT ONLY. Sup W/ #70</del>
84	65.	Chamberlain, J.C. et al., DNA polymorphisms at the lipoprotein lipase gene: associations in normal and hypertriglyceridaemic subjects, <u>Atherosclerosis</u> , 79(1):85-91 (Sep 1989).
	66.	Georges, J. L. et al., Family study of lipoprotein lipase gene polymorphisms and plasma triglyceride levels, <u>Genet epidemiol</u> , 13(2):179-92 (1996).
	67.	Mitchell, R. J. et al., DNA polymorphisms at the lipoprotein lipase gene and their association with quantitative variation in plasma high-density lipoproteins and triacylglycerides, <u>Hum Biol</u> , 66(3):383-97 (Jun 1994). ABSTRACT ONLY
	68.	Minnich A. et al., Lipoprotein lipase gene mutations in coronary artery disease, <u>Can J. Cardiol</u> , 14(5):711-6 (May 1998). ABSTRACT ONLY.
	69.	Templeton, A. R. et al., "Recombinational and mutational hotspots within the human lipoprotein lipase gene," <u>Am. J. Hum. Genet.</u> , 66(15):69-83 (2000)
↓	70.	Ahn, Y. I. et al., "Two DNA polymorphisms in the lipoprotein lipase and their associations with factors related to cardiovascular disease," <u>J Lipid Res</u> , 34(8):421-428 (1993)
	71.	<del>Chamberlain, J. C. et al., "DNA polymorphisms at the lipoprotein lipase gene associations in normal and hypertriglycerides subjects," <u>Atherosclerosis</u>, 79(1):85-91 ABSTRACT ONLY (1989) Sup W/ #5</del>

EXAMINER

8. Goldberg

DATE CONSIDERED

1/9/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

7316.1